Head-to-head · WeighScore
ElixaMD vs Omada Health
The verdict
ElixaMD takes it — 63.5/100 to 55.6/100.
ElixaMD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. ElixaMD is a doctor-guided online weight-loss telehealth offering compounded semaglutide injections from $179 the first month, with free shipping, no membership, no contract, and no insurance required.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | ElixaMD | Omada Health |
|---|---|---|
| WeighScore | 63.5/100 | 55.6/100 |
| Grade | C | C |
| Scorecard rank | #257 | #436 |
| Semaglutide | $179/mo (starting dose, first-month rate, compounded) | Not disclosed |
| Tirzepatide | Not disclosed | Not disclosed |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #257 · C
Strengths
- Compounded semaglutide from $179 first month with free shipping, no membership, no contract, and no insurance required
- Genuinely all-inclusive: 1:1 physician guidance, free dietician visits and care coaching, 24/7 support, and an all-in-one patient portal
- Names its compounding pharmacies (RedRock Pharmacy, Beaker Pharmacy) — more transparent than most compounded sellers
- HSA/FSA eligible; full legal suite (Terms, Privacy, Privacy Practices, Refund, Medical Consent, California Bill of Rights)
Where it loses points
- $179 is a first-month/intro price — ongoing monthly cost is higher (tiers to ~$249-$299)
- Compounded semaglutide is not FDA-approved (the site discloses this) — not brand Wegovy or Ozempic
- Appears to offer compounded semaglutide only — tirzepatide is not advertised
- Displays a generic LegitScript Certified badge but no verifiable seal/listing; state-availability list not published
Graded #436 · C
Strengths
- Added GLP-1 prescribing and medication management in late 2025
- Clinicians trained in obesity care, available in all 50 states
- Behavioral support wrapped before, during and after treatment
- GLP-1 Flex Care adds a cash-pay medication pathway in 2026
- Publicly traded, evidence-based virtual care platform
Where it loses points
- Core program distributed via employers and health plans, limited cash-pay
- GLP-1 prescribing is a recent addition still scaling
- GLP-1 Flex Care only rolling out to employers later in 2026
- No transparent published price for the core member program
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.